Navigation Links
Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome
Date:7/22/2014

ldhood epilepsies.

"LGS is a severely disabling condition. Some of these children have very frequent seizures – up to several a day – despite high doses of multiple antiepileptic medications. eTNS is a promising new approach to the treatment of drug-resistant epilepsy in general, and we are eager to find out whether it could be helpful in this very challenging subset of patients," said Dr. Shewmon.

"Children with LGS are often severely drug resistant, and continue to have frequent seizures despite trying multiple antiepileptic medications, often in combination.  These children can be injured when they fall during drop attacks, a problem that frequently persists into adulthood. Helping children and their families deal with the symptoms and the severe disability of LGS represents a significant unmet clinical need," added Christopher DeGiorgio, M.D., NeuroSigma's Vice President of Neurology and the Professor of Neurology at UCLA who first investigated eTNS for DRE.  "Recent data from European clinical use of our eTNS therapy suggests that it is safe to use in children, and we're eager to learn what benefits can be detected with eTNS therapy in children with LGS." 

"We are delighted that Dr. Shewmon and his collaborators at Olive View have begun enrolling children into this trial.  Besides possibly affording better control of seizures, our adjunctive treatment may lessen the need for antiepileptic drugs and thus allow children to avoid the medication side effects that can interfere with schoolwork and social development," noted Leon Ekchian, Ph.D., NeuroSigma's President and CEO.

Background – The Monarch eTNS System from NeuroSigma

In August 2012, NeuroSigma received CE Mark approval to market NeuroSigma's first trigeminal nerve stimulation (TNS) product, the Monarch™ eTNS™ System, in the European Union, for the adjunctive treatment of ep
'/>"/>

SOURCE NeuroSigma
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data
2. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
3. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
4. Irvine Center for Clinical Research Announces Open Enrollment for New Low Testosterone Study
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
7. AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
8. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
9. Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1
10. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
11. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... prospects for leading ophthalmic drug companies  What ... pharma ophthalmic industry ? Visiongain,s brand new report ... opportunities and prospects there. Our 242-page report ... lucrative areas in the industry and the future market ...
(Date:3/27/2015)... 27, 2015 The International Myeloma Foundation (IMF) ... while working toward prevention and a cure – today ... a federal resolution (H. Res. 174) that supports the ... Multiple Myeloma Awareness Month." Currently there are ... more than 110,000 new cases are diagnosed yearly, according ...
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... Nov. 9 New data from the JUPITER,study ... major cardiovascular (CV) events (defined in this,study as ... hospitalization for unstable angina, or death from CV,causes) ... among men and women,with elevated hsCRP but low ...
... 7 Data from an investigational,open-label, randomized ... alfa) in treating anemia in subjects with ... were presented today at the American Society,of ... dosing groups, including the FDA-approved,three-times-per-week (TIW) regimen, ...
Cached Medicine Technology:CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study 2CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study 3CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study 4CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... Portland, OR (PRWEB) March 28, 2015 ... in the media regarding recent changes and proposals around ... TV , current and former collegiate student-athletes across a ... experiences and reflect on common challenges. The special panel ... the country in sports ranging from football, track and ...
(Date:3/28/2015)... Healthpointe’s otolaryngologists, medical practitioners who attend ... disorders, are now offering a wide variety of treatments ... characterized by the presence of phantom sounds or ringing ... is a prevalent symptom that can arise due to ... tinnitus can impede a person’s quality of life. , ...
(Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Purity ... dietary supplements announces the release of their revolutionary ... shown in two randomized, double-blind, placebo-controlled clinical studies ... waist and hip size. MuffinStop™ is a combination ... and Garcinia mangostana, fused together to create one ...
Breaking Medicine News(10 mins):Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... medicines will no longer be available to Canadians from supermarkets ... are aimed at preventing addicts from making crystal meth. //The ... be affected by the ban which will come into force ... sell about 15 medicines which are of the single ingredient ...
... might soon have a vaccine to combat a disease (cervical ... Merck had submitted details of a cervical cancer vaccine, // ... types of infection with the human papilloma virus (HPV) to ... ,Another vaccine, developed by GlaxoSmithKline wound soon be approved for ...
... Medical Sciences has revealed that early stroke and dementia maybe due ... Incidences of blood pressure at an early age should not be ... a lesser blood flow to it due to hypertension, thus raising ... ,This has been confirmed in as many as 33% ...
... rate of intentional injury. This includes cases like suicide and ... a mental health advocate blames the mental health service or ... higher than that seen in Adelaide. He is calling ... kindly donate money to improve the child and adolescent health ...
... Department of Health Services would be banning Mexican candies with ... high levels of lead// in Mexican candies the Officials ... high amount of lead. It is known that there are ... Government is planning to have stringent quality check testing of ...
... treatment for cancer is a drug or substance that stops ... obliterating// or stopping cancer to spread. ,With the same ... report that a compound related to vitamin A is useful ... preventing or slowing tumour growth in mice prone to lung ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Show Promise In Prevention 2Health News:A treatment for lung cancer: similar to Vitamin A but with few side effects. 2
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Solid 13.5 mm wide by 5 mm deep blades. Edge of blades serrated. Dull finish....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: